Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 6/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | NRP1 | O14786 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801717 | 0.96 | GRB2 (0.51) | ACENTSR2NTSR1F2GRB2 | |
| SCHEMBL29571867 | 0.95 | F2 (0.46) | ACENTSR2NTSR1F2GRB2 | |
| SCHEMBL29801939 | 0.95 | ACE (0.50) | ACENTSR2NTSR1F2GRB2 | |
| SCHEMBL29802097 | 0.94 | ACE (0.50) | ACENTSR2NTSR1OPRM1APLNR | |
| SCHEMBL29802139 | 0.94 | F2 (0.49) | ACENTSR2NTSR1F2GRB2 | |
| SCHEMBL29801996 | 0.94 | ACE (0.47) | ACENTSR2NTSR1F2GRB2 | |
| SCHEMBL29445609 | 0.92 | F2 (0.57) | NTSR2NTSR1F2GRB2NRP1 | |
| SCHEMBL29802257 | 0.91 | NRP1 (0.53) | ACENTSR2NTSR1F2GRB2 | |
| SCHEMBL29802028 | 0.90 | GRB2 (0.48) | ACENTSR2NTSR1F2GRB2 | |
| SCHEMBL29802048 | 0.90 | GRB2 (0.52) | ACENTSR2NTSR1F2GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | ACE 277/4885NTSR2 1758/4885NTSR1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.